Assignment history

Inventors

The sole named inventor for US Patent 12324873 is Michael Ragusa. At the time of the patent application filing (2024-11-21), Michael Ragusa was an inventor whose rights were assigned to Haemonetics Corp. The patent record indicates that on 2024-12-17, the assignor's interest was assigned to Haemonetics Corporation, which is a standard practice for employees assigning intellectual property to their employer.

Original assignee

The original assignee named on the issued patent is Haemonetics Corp.

Haemonetics Corp is a global provider of medical products and solutions primarily focused on blood and plasma component collection, surgical blood management, and hospital transfusion services. They ship various products embodying blood processing technologies, including apheresis systems like those described in the patent, which automate blood donation and separation processes. The company is publicly traded on the New York Stock Exchange under the ticker HAE and is currently operating.

Assignment timeline

A search of the USPTO Assignment Center for US12324873 reveals one recorded assignment of assignor's interest to the current assignee.

• 2024-12-17 (execution likely same day or earlier) / recorded 2024-12-17 (per Google Patents Legal Events)
  • Conveyance: Assignment of Assignor's Interest
  • Assignor: Ragusa, Michael
  • Assignee: HAEMONETICS CORPORATION
  • Correspondent: Not explicitly detailed in the provided Google Patents snippet; actual document on USPTO Assignment Center would contain this.
  • Context: Internal reorg (inventor to corporate assignee transfer)

Timeline diagram

timeline
    title Ownership of US 12324873
    2024 : Filed by Michael Ragusa
         : Assigned to Haemonetics Corp
    2025 : Issued to Haemonetics Corp

NPE / troll-pattern signals

1. Shell-entity transfer — Not present. The only recorded assignment is from the individual inventor to Haemonetics Corp, which is a publicly traded operating company. There is no indication of transfer to a licensing-only LLC.
2. Known asserter in the chain — Not present. Haemonetics Corp is an operating company and not identified as a known NPE.
3. Repeat correspondent across the chain — Unclear. The correspondent information for the inventor-to-assignee transfer is not explicitly provided in the available patent summary. Without accessing the full USPTO assignment record, this cannot be determined.
4. Cascading transfers — Not present. Only one assignment is recorded in the ownership chain (inventor to original assignee).
5. Pre-litigation transfer — Not present. The assignment from Michael Ragusa to Haemonetics Corp occurred on 2024-12-17, prior to the patent's issuance date (2025-06-10) and before the first documented litigation in Colorado District Court (case number 1:25-cv-01409, implying a 2025 filing) or the PTAB case (PGR2026-00009, implying a 2026 filing). This is a standard pre-issuance assignment.
6. Bankruptcy fire-sale — Not present. Haemonetics Corp is an active, publicly traded company. There is no indication of bankruptcy.
7. Privateering — Not present. There is no evidence of an operating company transferring the patent to an NPE for assertion. The patent remains with the original operating assignee.
8. Defensive aggregator (anti-NPE) — Not present. The patent remains with Haemonetics Corp, an operating company, and has not been transferred to a defensive aggregator.

Verdict

Operating-company assertion. The patent US12324873 is currently owned by Haemonetics Corp, a publicly traded operating company that manufactures and sells blood processing systems. The only recorded assignment is a standard transfer from the inventor to the corporate assignee. While there is active litigation, it is presumed that Haemonetics Corp is asserting its own patent as an operating company.

Verification: USPTO Patent Assignment Search (Search for patent number 12324873).